Tumor cells rely on glycolysis to meet their elevated demand for energy. Thereby they produce significant amounts of lactate and protons, which are exported via monocarboxylate transporters (MCTs), supporting the formation of an acidic microenvironment. The present study demonstrates that carbonic anhydrase IX (CAIX), one of the major acid/base regulators in cancer cells, forms a protein complex with MCT1 and MCT4 in tissue samples from human breast cancer patients, but not healthy breast tissue. Formation of this transport metabolon requires binding of CAIX to the Ig1 domain of the MCT1/4 chaperon CD147 and is required for CAIX-mediated facilitation of MCT1/4 activity. Application of an antibody, directed against the CD147-Ig1 domain, displaces CAIX from the transporter and suppresses CAIX-mediated facilitation of proton-coupled lactate transport. In cancer cells, this "metabolon disruption" results in a decrease in lactate transport, reduced glycolysis, and ultimately reduced cell proliferation. Taken together, the study shows that carbonic anhydrases form transport metabolons with acid/base transporters in human tumor tissue and that these interactions can be exploited to interfere with tumor metabolism and proliferation.
Introduction
Despite substantial progress in early detection and tumor therapy, breast cancer is still the most commonly diagnosed form of cancer and leading cause of cancer death in women worldwide [1] . Like most solid tumors, breast tumor tissue displays a significant increase in glycolytic activity, as compared with healthy breast tissue [2] . Glycolysis results in production of lactate and H + , which have to be removed from the cell to avoid intracellular acidosis and suffocation of metabolism. Lactate flux in cancer cells is primarily mediated by the monocarboxylate transporters MCT1 and MCT4, which transport lactate together with H + in a 1:1 stoichiometry [3] [4] [5] [6] . Expression of both MCT1 and MCT4 is increased in breast cancer tissue, as compared with healthy breast epithelium, and correlates with increasing tumor grade [7] [8] [9] [10] [11] [12] . Furthermore, overexpression of MCT1 was shown to correlate with shorter progression-free survival and increased risk of recurrence after chemotherapy in breast cancer patients [2, 7] .
Trafficking of MCTs to the plasma membrane and regulation of transport function is mediated by ancillary proteins. For MCT1/4 the preferred ancillary protein is CD147, which is associated with the transporter in the membrane [13] [14] [15] . The general isoform of CD147 (also termed basigin), which is ubiquitously expressed in most tissue, comprises two extracellular, immunoglobulin (Ig)-like domains, a transmembrane domain and a short intracellular C-terminal tail [16, 17] . CD147 is a multifunctional protein, which plays a key role in the development and progression of different tumor types, including breast cancer [18] [19] [20] [21] . Expression of CD147 is upregulated in breast cancer tissue, as compared with normal breast tissue [7] . It is subsequently upregulated with increasing histological grade [7, 12] and positively correlates with poor prognosis and chemoresistance [7, 19, 21] . Transport activity of MCTs is facilitated by carbonic anhydrase IX (CAIX), an enzyme that has been attributed a central role in tumor acid/base regulation and cancer progression [22] [23] [24] [25] [26] [27] . CAIX is tethered to the extracellular face of the plasma membrane via a transmembrane domain. Furthermore, it features a proteoglycan-like (PG) domain, which is unique to CAIX within the CA family [25] . In healthy tissue, expression of CAIX, which is under control of HIF-1α [28] , is restricted to intestine and gall bladder [29] . However, CAIX is upregulated in many different tumor types, including breast cancer [30, 31] . Expression levels of CAIX positively correlate with histological tumor grade in breast cancer [9] [10] [11] [31] [32] [33] [34] [35] [36] [37] . Furthermore, expression of CAIX was found to correlate with reduced overall survival and higher occurrence of relapse and is associated with chemoresistance in breast cancer patients [31, 38, 39] . Interestingly, expression of CAIX was also found to correlate with MCT1 and CD147 in breast tumor tissue [31] .
We have previously shown that CAIX facilitates MCT transport activity in breast cancer cells and when coexpressed in Xenopus oocytes, by a mechanism that is independent from the enzyme's catalytic function [26, 27] . In the present study, we investigate whether CAIX forms a "transport metabolon" (a structural and functional complex, composed of a transport protein and an enzyme, which interact with each other to facilitate substrate transport across the cell membrane [40] [41] [42] ) with MCT1/4 in human breast cancer tissue and analyze the structural components that mediate the formation of this protein complex. Furthermore, we elaborate whether the MCT1/4-CAIX transport metabolon can be exploited as drug target for tumor therapy.
Results

CAIX interacts with MCT1 and MCT4 in human breast cancer cells
Lactate efflux from cancer cells is primarily mediated by MCT1/4 [7, 8, 43] , the activity of which is facilitated by CAIX, which functions as proton antenna for the transporter [26, 27] . In order to establish an efficient proton transfer, enzyme, and transporter must be closely colocalized. To investigate whether CAIX forms such a "transport metabolon" with MCTs in human breast cancer tissue, we analyzed the physical interaction between CAIX and MCT1/4, using in situ proximity ligation assays (PLA). CAIX was found to interact with MCT1/4 in tumor samples from breast cancer patients ( Fig. 1a -c, f-h), but not normal breast tissue, which does not express CAIX ( Fig. 1d , i). The number of MCT1-CAIX complexes increased in samples from grade II and grade III tumors, as compared with grade I tumors ( Fig. 1e ). While no significant changes in the number of MCT4-CAIX complexes were detected between grade I and grade II tumors, grade III tumors showed a significant increase in the number of MCT4-CAIX interactions ( Fig. 1j ). When MCT1 and MCT4 are considered together, the number of transport metabolons constantly increases with increasing tumor grade from 13 signals/cell in grade I, 20 signals/cell in grade II and 30 signals/cell in grade III tumors.
Expression of CAIX and MCT4 are controlled by HIF-1α. Therefore, it appears likely that the MCT-CAIX transport metabolons will primarily form under hypoxia. Indeed, the number of interactions between MCT1/4 and CAIX more than doubled in MDA-MB-231 cells, incubated under hypoxia (1% O 2 ), as compared with normoxic cells ( Fig. 2a, b ). In MCF-7 cells, hypoxia induced a more than threefold increase in MCT1-CAIX interactions (Fig.  2c ). In both cell lines, knockdown of CAIX resulted in a significant decrease in the PLA signal, while omission of the primary antibodies resulted in no signal at all ( Fig.  2a 3 -a 5 , b 3 -b 5 , c 3 -c 5 ). In MCF-7 cells, which do not express MCT4 [26] , no signals where observed when the assay was carried out with antibodies against MCT4 and CAIX ( Fig.  2c 5 ). Colocalization of MCT1/4 and CAIX was also confirmed by immune staining for MCT1, MCT4, and CAIX in MDA-MB-231 and MCF-7 cells (Fig. S1 ). Taken together, these results indicate that MCT1 and MCT4 can form a protein complex with CAIX in hypoxic breast cancer cells.
CAIX binds to the Ig1 domain of the MCT1/4 chaperon CD147
Direct interaction between MCT1/4 and CAIX requires binding between the proteins. We have recently shown that extracellular CAIV does not directly bind to MCT1/4, but to the Ig1 domain in the transporters' chaperon CD147 [44] . Binding of CAIX to CD147 was tested by pulldown of CAIX with a GST fusion protein of the CD147-Ig1 domain ( Fig. 3 ). Pulldown of CAIX with CD147-WT resulted in a robust signal for CAIX, indicating direct binding between the two proteins ( Fig. 3b, c) . Molecular docking experiments suggested that binding between CD147 and CAIX is mediated by CD147-Glu73 or CD147-Glu31 and CAIX-His200 ( Fig. 3a) . Indeed, mutation of CD147-Glu73 and CAIX-His200 resulted in a loss of interaction, while mutation of CD147-Glu31 had no significant effect (Fig. 3b , c). Equal expression levels of CAIX-WT and CAIX-H200A in Xenopus oocytes, used for the pulldown, were confirmed by western blot (Fig. S2a ). In summary, the pulldown shows that CAIX binds to the Ig1 domain of CD147, most likely by forming a hydrogen bond between CAIX-His200 and CD147-Glu73.
CAIX-mediated facilitation of MCT transport activity requires binding of CAIX to CD147
To investigate whether binding of CAIX to CD147 is required for CAIX-mediated facilitation of MCT transport activity, we coexpressed rat MCT1 together with rat CD147-WT or a mutant of the chaperon and CAIX in Xenopus oocytes ( Fig. 3d ). Coexpression of MCT1 and rCD147-WT with CAIX resulted in a significant increase in MCT1 transport activity ( Fig. 3e, S2b ). Mutation of rCD147-Lys73 (the analog to hCD147-Glu73), but not rCD147-Glu32 (analog to hCD147-Glu31), resulted in a loss of functional interaction between MCT1 and CAIX ( Fig. 3e, S2b ). Mutation of rCD147 had no effect on MCT1 transport activity in the absence of CAIX ( Fig. 3e , S2b). Expression of CAIX was confirmed by a CO 2 pulse at the end of each experiment (Fig. 3d, S2c ). We previously confirmed that CAIX-His200 is crucial for the functional interaction between MCT1 and CAIX (see Fig. 4 in [26] ). To confirm that binding of CAIX to rCD147 follows the same mechanism as observed for hCD147, CAIX was pulled down with a GST fusion protein of the rCD147 Ig1 domain or mutants of the proteins (Fig. S2d, e ). As with hCD147, the pull down of CAIX with rCD147 and mutants showed similar binding mechanisms.
Transport of lactate in cancer cells is primarily mediated by MCT1/4. However, some cancer cells, including breast carcinoma, also express MCT2 [8] , the chaperon of which is GP70 [14] . The Ig1 domain of GP70 carries a putative CAIX binding site (GP70-Asp95, GP70-Arg130) that is analogous to the binding site in CD147 ( Fig. S3a ). Coexpression of MCT2, GP70, and CAIX in Xenopus oocytes and pulldown of CAIX with GST-GP70 reviled that CAIX could bind to GP70-Arg130 to form a transport metabolon with MCT2 ( Fig. S3 ). 
Functional interaction between MCT and CAIX can be disrupted by an antibody against CD147
Since CAIX is predominately expressed in cancer cells, the MCT1/4-CD147-CAIX transport metabolon is a promising target to interfere with H + -coupled lactate transport in cancer cells. Therefore, we investigated whether the CAIXmediated increase in MCT transport activity could be abolished by suppressing binding of CAIX to the transporter's chaperon. The displacement of CA from a transporter was termed "metabolon disruption" [45] . Preincubation with an antibody, directed against an epitope in the Ig1 domain of CD147, which is situated close to the CAIX binding site ( Fig. 4a ), abolished the CAIX-mediated increase in MCT4 transport activity in Xenopus oocytes (Fig. 4b, c ). Anti-CD147 did not influence MCT4 transport activity in the absence of CAIX, indicating that binding of the antibody to CD147 that does not disrupt the MCT4-CD147 complex ( Fig. 4c ). Furthermore, anti-CD147 did not alter CAIX catalytic activity ( Fig. 4b, S4g ). Incubation of oocytes with anti-CD147 induced no changes in the expression levels of MCT4, CAIX, and CD147 ( Fig. S4a-f ).
In hypoxic MCF-7 cells, application of anti-CD147 disrupted the transport metabolon, as shown by in situ PLA ( Fig. 4d-h ). Metabolon disruption resulted in a significant decrease in lactate transport capacity in hypoxic MDA-MB-231 and MCF-7 cells ( Fig. 4i -l, S5a, b). Pre-incubation with anti-CD147 did not change surface expression of the lactate transporter in hypoxic MDA-MB-231 cells, as shown by surface biotinylation of MCT4 ( Fig. S5c, d ). To investigate how anti-CD147-induced metabolon disruption affects cancer cell metabolism, we measured acid production in hypoxic MDA-MB-231 and MCF-7 cells in the presence of anti-CD147 or the MCT inhibitors AR-C155858 (AR-C) and syrosingopine (Syro) ( Fig. 5a-d ). (AR-C inhibits MCT1 transport activity with a K i of~2 nM, but does not inhibit activity of MCT4 [46] . Syro was recently found to inhibit transport activity of MCT1 and MCT4 with IC 50 values of~2.5 µM and~40 nM, respectively [47] . Since the MCF-7 cells used in this study only express MCT1 [26] , lactate transport in MCF-7 was inhibited with 300 nM AR-C. In MDA-MB-231 cells, which express both MCT1 and MCT4 [26] , lactate transport was inhibited with a cocktail of 300 nM AR-C and 10 µM of Syro.) Application of anti-CD147 decreased the rate of extracellular acidification by 40% in MDA-MB-231 and 30% in MCF-7 cells, while full inhibition of MCT transport activity resulted in a reduction of acidification by around 80% (Fig. 5a-d ). In line with these results, anti-CD147 reduced lactate production by 48% in MDA-MB-231 and 38% in MCF-7 cells (Fig. 5e, f) . Full inhibition of MCT transport activity reduced lactate production by 76% in MDA-MB-231 and 53% in MCF-7 cells (Fig. 5e, f) . Inhibition of lactate transport by AR-C and AR-C + Syro in MCF-7 and MDA-MB-231 cells, respectively, was confirmed by lactate imaging (Fig. 5g, h) .
To investigate how metabolon disruption affects cancer cell proliferation, we determined the number of hypoxic MDA-MB-231 and MCF-7 cells for up to 3 days in the presence of anti-CD147 (10 µg/ml) or Syro and/or AR-C ( Fig. 6 ). Anti-CD147 reduced proliferation of MDA-MB-231 and MCF-7 cells by 62-74% and 67-85%, respectively ( Fig. 6c, d ). Inhibition of MCT transport activity with Syro and/or AR-C decreased proliferation of MDA-MB-231 and MCF-7 cells by 85-87% and 82-88%, respectively ( Fig. 6c,  d) . Application of anti-CD147 at a concentration of 5 µg/ml resulted in a lower reduction in proliferation of MDA-MB-231 (22-50%) and MCF-7 cells (45-68%) ( Fig. S6 ). 
Discussion
The present study shows that carbonic anhydrase IX forms a transport metabolon with the two major H + /lactate extruders MCT1 and MCT4 in human tumor tissue, but not in healthy breast tissue. The number of transport metabolons increased with higher tumor grade, with the number of MCT1-CAIX metabolons increasing from grade I to grade II and the number of MCT4-CAIX metabolons increasing from grade II to grade III. In line with this, others have shown that CAIX is expressed in breast tumors, but absent in healthy breast tissue [48] and that expression of CAIX, MCT1, and MCT4, positively correlate with tumor grade and poor prognosis [2, 7, [9] [10] [11] [31] [32] [33] [34] [35] [36] [37] .
It was recently demonstrated by sequential PET/CT and MRI that glycolytic activity increases with higher tumor grade in breast cancer patients [49] . These results are in agreeance with our findings that the number of MCT1/ 4-CAIX transport metabolons increases with higher tumor grade in breast tumor tissue samples. Since a higher glycolytic rate results in increased production of lactate and protons, these cells would also require a higher H + /lactate efflux capacity, which could be met by an increased amount of MCT1/4-CAIX transport metabolons in the cell membrane. The necessity for an increasing number of MCT1/ 4-CAIX transport metabolons in higher-grade tumors could also derive from progressing restriction of acid removal. MRI studies on breast cancer patients demonstrated that the apparent diffusion coefficient decreased with higher tumor grade [49] [50] [51] , indicating reduced venting of protons from the tumor mass [52] . In such an environment, efficient proton handling seems crucial for proton-coupled lactate transport across the membrane. We have previously suggested that intracellular and extracellular carbonic anhydrases can function as "proton antennae" for MCTs by mediating the rapid exchange of protons between the transporter pore and the surrounding protonatable residues [26, [53] [54] [55] [56] . In CAIX, proton transfer between MCT and surrounding protonatable residues seems to be mediated by acidic residues within the enzyme's proteoglycan-like domain [27] . Rapid H + transfer between protonatable sites can be mediated by electrostatic repulsion caused by overlapping Coulomb cages, which would require a maximum distance below 1 nm between the involved residues [57] [58] [59] . Close proximity could be achieved by direct binding of the proteins. In the present study, we demonstrate that CAIX binds to the Ig1 domain of CD147 (and GP70). CD147 binding is mediated by Glu73 (Lys73 in rat CD147 and Arg130 in rat/human GP70), while in CAIX binding requires His200. Molecular docking shows that CD147-Glu73 can form a hydrogen bond with CAIX-His200 in the "in" confirmation, with a distance of 2.1 Å between the two binding partners (Fig. 7a) . Binding of the chaperon to CAIX-His200 is mediated either by an acidic residue (hCD147-Glu73), which serves as proton acceptor in a hydrogen bond, or an alkaline residue (rCD147-Lys73 or r/hGP70-Arg130), which serves as proton acceptor. Therefore, CAIX-His200 must either serve as proton donor or proton acceptor, depending on its binding partner. We could previously show that CAIV-His88 (the homolog to CAIX-His200) which binds to the Ig1 domain of CD147 and GP70, can indeed either serve as hydrogen donor or hydrogen acceptor, depending on whether it binds to hCD147-Glu73 or to rCD147-Lys73 / hGP70-Arg130 [44] . Therefore, it can be assumed that CAIX-His200 also forms a hydrogen bond with hCD147-Glu73, rCD147-Lys73, and hGP70-Arg130. This binding would bring CAIX close enough to the transport pore to establish an efficient proton shuttle between transporter and enzyme. Indeed, mutation of either rCD147-Lys73 or CAIX-His200 does not only result in a loss of binding between CD147 and CAIX, but also in a loss of functional interaction between MCT1/4 and CAIX (for CAIX-His200, see Fig. 4 in [26] ). Interestingly, CAIX-His200, which serves as binding site for CD147/ GP70, does also represent the critical residue of the enzyme's intramolecular H + shuttle. We recently showed for intracellular isoform CAII, that CAII-His64 (the critical residue of the enzyme's intramolecular H + shuttle), mediates binding of the enzyme to an acidic cluster in the MCT1/4 C-terminal tail [60, 61] , but is not involved in the transfer of protons between transporter and enzyme [55] . This proton transfer is instead mediated by the two acidic residues CAII-Glu69 and CAII-Asp72 at the protein surface [55] . The catalytic domain of CAIX does not seem to feature a homolog cluster to CAII-Glu69/Asp72, however, the CAIX PG domain features 18 Glu and 8 Asp residues, which have been suggested to function as an intramolecular proton buffer [62] . Truncation of the PG domain resulted in a loss of functional interaction between MCT1/4 and CAIX [27] , even though in this study binding of CAIX to CD147 persisted after truncation (Fig. S2e) . Taken together, the data indicate that CAIX, which binds to the Ig1 domain of the MCT chaperon CD147 (or GP70) via CAIX-His200, facilitates the acidic residues in its PG domain to rapidly exchange protons between transporter pore and the surrounding protonatable residues (Fig. 7b 1 ) . This rapid Inhibition of CAIX catalytic activity has been widely considered as a potential therapeutic strategy for hypoxic tumors [63] . However, most of the inhibitors tested so far bind to a moiety apart from His200 and might therefore not target the direct and functional interaction between Fig. 7 Model of the MCT1/4-CD147-CAIX transport metabolon. a Structural model of the physical interaction between CAIX and CD147. CAIX (green structure) binds to the Ig1 domain of CD147 (ochre structure) by formation of a hydrogen bond (dotted line) between CD147-Glu73 and CAIX-His200 in the "in" confirmation (red sticks), with a distance of 2.1 Å between the two binding partners. b 1 Glycolysis serves as the prime energy source for hypoxic cancer cells, leading to vast production of lactate and protons which have to be removed from the cell to avoid intracellular acidosis and suffocation of cell metabolism. Under these conditions CAIX, which is directly bound to the Ig1 domain of the MCT1/4 chaperon CD147, serves as a proton antenna for the transporter which rapidly exchanges H + between transporter pore and surrounding protonatable residues (blue-gray circles) at the extracellular site of the plasma membrane. Fast removal of H + counteracts the formation of proton microdomains around the transporter pore and drives the efflux of lactate and protons from the cell. Cytosolic CAII, which is directly bound to the MCT1/4 C-terminal tail, serves as the intracellular counterpart to CAIX. CAII collects H + from surrounding protonatable residues at the inner face of the plasma membrane and shuttles them to the transporter pore. b 2 Binding of anti-CD147 to an epitope close to the CAIX binding site in the Ig1 domain of CD147, drives CAIX away from the MCT1/ 4-CD147 complex. This disruption of the transport metabolon leads to a decrease in MCT1/4 transport capacity, resulting in intracellular accumulation of lactate and protons, which in turn leads to a decrease in glycolytic activity and ultimately a reduction in cell proliferation MCT1/4-CD147 and CAIX [64] . To test whether disruption of the MCT-CD147-CAIX transport metabolon could impact cancer cell metabolism and decrease cell proliferation we used an antibody against CD147 (anti-CD147), which targets a moiety close to the CD147-Glu73. Application of anti-CD147 resulted in the total loss of CAIX-induced increase in MCT4 transport activity in Xenopus oocytes, indicating that the antibody does indeed disrupt the interaction between MCT1-CD147 and CAIX. In MCF-7 and MDA-MB-231 cancer cells, disruption of the transport metabolon resulted in a significant reduction, but no full inhibition of lactate flux. This is not surprising as MCT transport activity is increased by carbonic anhydrases, but MCTs are already active in the absence of the enzyme. However, disruption of the transport metabolon with anti-CD147 resulted in a significant decrease in lactate and proton production and ultimately a decrease in cell proliferation. These results indicate that disruption of the transport metabolon results in a decrease of MCT transport activity, which leads to intracellular lactate accumulation and inhibition of glycolytic activity, which in turn results in decreased cell proliferation ( Fig. 7b 2 ) .
Direct inhibition of MCT transport activity by small molecule inhibitors like AR-C155858, AZD3965, syrosingopine or diclofenac is considered a therapeutic strategy for tumor treatment [47, [65] [66] [67] [68] . Since metabolon disruption reduces, but not fully abolishes MCT transport activity, direct inhibition of MCT1/4 seems more efficient for cancer treatment on the cellular level. However, MCTs are ubiquitously expressed in the human body and play a central function in the energy metabolism of a wide range of tissues, including heart and skeletal muscle, liver and brain [68] [69] [70] [71] . Therefore, systemic application of a high dose of MCT inhibitors, which would be required for full inhibition of MCT transport activity in a tumor, could be expected to produce severe side effects in other tissues. Therefore, systemic administration of a MCT inhibitor could only aim to reduce, but not full inhibit, MCT transport activity within the tumor. CAIX, however, is expressed in few healthy tissues, including stomach and gallbladder, but highly upregulated in many solid tumors [29] . Therefore, targeted disruption of the MCT-CD147-CAIX transport metabolon should cause fewer side effects in other tissue than direct targeting of MCT transport function. However, such targeted inhibition has to be directed against CAIX, which is the only part of the MCT-CD147-CAIX metabolon that is exclusively expressed in cancer cells. We therefore suggest a screen for small molecule inhibitors or antibodies against CAIX, which could interfere with binding of the enzyme to CD147, to selectively reduce lactate transport capacity in cancer cells, without interfering with lactate flux in healthy tissue.
Materials and methods
Tissue micro array
Human breast tissue micro arrays were purchased from Novus Biological, Wiesbaden, Germany (NBP2-47174). The specifications of the arrays are given in Supplementary  Table 1 .
Cultivation of breast cancer cell lines MCF-7 and MDA-MB-231 cells were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). If not mentioned otherwise, both cell lines were cultured in RPMI-1640 medium with L-glutamine and NaHCO 3 (R8758, Sigma-Aldrich/Merck, Darmstadt, Germany), supplemented with 10% fetal bovine serum (F7524, Sigma), and 1% penicillinstreptomycin (P4333, Sigma). Cells were either incubated under normoxia (95% air, 5% CO 2 ) or under hypoxia (94% N 2 , 5% CO 2 , 1% O 2 ). Both cell lines were subcultivated for a maximum of 20 passages, authenticated in September 2019 (Eurofins Genomics Germany GmbH, Ebersberg, Germany) and regularly tested negative for contamination with mycoplasma.
Interfering antibodies and inhibitors
Mouse monoclonal anti-CD147, directed against amino acids 13-51 of hCD147, was purchased from Santa Cruz Biotechnology (SCBT), Heidelberg, Germany (sc-374101). Before the antibody was used on living cells, NaN 3 was removed using a protein concentrator centrifuge column (No. 88516; Thermo-Fisher Scientific, Braunschweig, Germany). AR-C15585 was purchased from Tocris/Bio-Techne, Wiesbaden, Germany (No. 4960). α-cyano-4hydroxycinnamic acid (CHC) and syrosingopine were purchased from Sigma (No. 476870 and SML1908, respectively).
In situ proximity ligation assay
Interaction between MCT1/4 and CAIX in tissue micro arrays and cell culture was examined using the Duolink® in situ PLA Kit (DUO92103, Sigma). The protocol for the PLA in cultivated cancer cells was described previously [55] . MCF-7 cells were cultured as described above. MDA-MB-231 cells were cultured in Leibovitz-L15 (11415; Thermo-Fisher), supplemented with 10% fetal calf serum (F413, Sigma), 1% penicillin/streptomycin (15149, Thermo-Fisher), 5 mM D-glucose (16325, Sigma). The PLA was carried out with the following antibodies: goat anti-MCT1 (T-19), sc-14917, SCBT, 1 µg/ml; goat anti-MCT4 (C-17), sc-14930, SCBT, 1 µg/ml; mouse anti-CAIX (M75) and rabbit anti-CAIX (IC), provided by Dr Silvia Pastorekova [72] , 1 µg/ml. Actin was stained with phalloidin (1:500, A12379, Life-Technologies/Thermo-Fisher or 1:1000, sc-363791, SCBT). Nuclei were stained with DAPI in the mounting medium (DUO82040, Sigma or P36931, Thermo-Fisher). Pictures were taken with a Zeiss LSM700 or Leica SP5 microscope, using a 40× oil immersion objective for cultures and a LSM700 with 25× oil immersion objective for tissue. Pictures were taken at random locations and the PLA signals were analyzed using ImageJ.
Antibody staining in cultured cancer cells
Antibody staining of cultured cells was described previously [26, 55] . Antibodies and concentrations were identical to the PLA. Pictures were taken with a Zeiss LSM700 microscope, using a 40× oil immersion objective.
Western Blot analysis
Protein quantification in Xenopus oocytes by western blot was described previously [73] . CAIX was labeled with mouse anti-CAIX (M75; [72] ; 0.4 µg/ml), MCT4 with rabbit anti-MCT4 (AB3314P, Millipore/Merck; 4 µg/ml), CD147 with mouse anti-CD147 (sc-374101, SCBT; 0.1 µg/ ml), and β-tubulin with mouse anti-β-tubulin (T5201, Sigma, 2 µg/ml). Quantification of the bands was carried out using ImageJ. CAIX, MCT4, and CD147 were normalized to β-tubulin in the same sample.
Pull-down of CAIX with GST fusion proteins
CAIX was pulled down with GST fusion proteins of CD147 and GP70, using the Pierce™ GST protein interaction pulldown Kit (21516, Thermo-Fisher), as previously described [44, 61] . For each pulldown, lysate from 30 CAIXexpressing oocytes was added to the beads. CAIX was labeled with mouse anti-CAIX (M75; [72] ; 0.4 µg/ml) and GST with mouse anti-GST-Tag (05-782, Merck; 2.5 µg/ ml). To account for variations in the amount of fusion protein, each signal for CAIX was normalized to the corresponding signal for GST.
Surface biotinylation
Hypoxic MDA-MB-231 cells were incubated with 1.5 mg/ ml of Sulfo-NHS-SS-Biotin (21331, Thermo-Fisher). After quenching with 200 mM glycine (G7126, Sigma), cells were lysed and debris removed by centrifugation. A total of 300 µL of lysate were used for the pull-down. Biotinylated proteins were pulled down with avidin-agarose beads (E2513, Sigma). Bound protein was eluted with 300 µL of 100 mM 1,4-dithiothreitol (6908, Carl-Roth GmbH, Karlsruhe, Germany) and analyzed by western blot. MCT4 was labeled with rabbit anti-MCT4 (AB3314P, Millipore/ Merck; 2 µg/ml).
Heterologous protein expression in Xenopus oocytes
Protein expression in Xenopus oocytes was carried out as previously described [74, 75] . The procedure for surgical removal of oocytes from adult female Xenopus laevis frogs was approved by the Landesuntersuchungsamt Rheinland-Pfalz (23 177-07/A07-2-003 §6) and the LAVES (33.19-42502-05-17A113). Oocytes were injected with 5 ng of cRNA coding for MCT1, MCT2, or MCT4, together with 10 ng of cRNA coding for rCD147 or rGP70, and 5 ng of cRNA coding for CAIX.
Measurements of intracellular H + concentrations in Xenopus oocytes
Determination of [H + ] i in Xenopus oocytes with ionsensitive microelectrodes was described previously [75, 76] . All measurements were carried out in oocyte saline, pH 7.0, at RT. The rate of change in [H + ] i was analyzed with OriginPro 8.6 (OriginLab Corporation, Northampton, Massachusetts). Recording and data analysis have been described previously [75] .
Lactate imaging in cancer cells
Changes in [lactate] i were measured using the lactatesensitive FRET nanosensor Laconic. The specifications of the sensor have been described previously [77] . Transduction of cancer cells with Laconic was described previously [26, 27] . Experiments were performed in HEPES-buffered saline (143 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1 mM Na 2 HPO 4 , 10 mM HEPES, 2 mM CaCl 2 , pH 7.2) at 21°C. Image acquisition was carried out with a Leica SP2 microscope, with a 20x dry objective. Laconic was excited at 458 nm and the emission light split into a 460-500 nm (mTFP) and a 520-550 nm (Venus) fraction. Pictures were taken at a sampling rate of 0.2 Hz. The mTFP fraction was divided by the Venus fraction. Data analysis was carried out with ImageJ and OriginPro 8.6.
Determination of proton and lactate production in cancer cells
Extracellular pH values of cultured cells were monitored for 24 h using a SensorDish® Reader (PreSens GmbH, Regensburg, Germany). Afterward, the medium was deproteinized using perchloric acid and KOH precipitation. Lactate concentrations were determined using the Megazyme L-Lactic Acid Assay Kit (Romer-Labs, Butzbach, Germany). Concentrations were normalized to cell number in each individual well.
Determination of cell proliferation
Cell proliferation was determined by counting of stained nuclei as previously described [26] .
Molecular docking of CD147 and CAIX CD147 and CAIX were docked and modeled as described previously [44, 61] . Docking was performed manually using COOT to maximize interface interactions followed by energy minimization at the complex interface using Crystallography and NMR System program (CNS) [78, 79] . The PDBs used to generate the model were 3B5H for hCD147 [80] and 4ZAO for CAIX [81] . Complexes were further analyzed and figures were generated using Pymol (Schrödinger, New York, NY).
Calculation and statistics
No statistical methods were used to predetermine sample size. Statistical values are presented as mean ± S.E.M. Significance in difference was calculated by One-Way ANOVA, followed by means comparison using Scheffé or Bonferroni test, depending on whether datasets show homogeneity of variance or not. Homogeneity of variance was assessed using Levene's test. Differences between pairs of data were tested using a paired-sample t-test. All tests were carried out using OriginPro 8.6. No outliers were removed from the analysis. A significance level of p ≤ 0.05 is marked with *; p ≤ 0.01 with ** and p ≤ 0.001 with ***.
